

MEETING ABSTRACT

Open Access

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips^{1,2*}, RL Milne², MA Rookus³, D Goldgar⁴, M Friedlander⁵, SA McLachlan⁶, S Buys⁷, AC Antoniou⁸, K Birch¹, MB Terry⁹, DF Easton⁸, P Weideman¹, M Daly¹⁰, N Andrieu¹¹, EM John¹², MJ Hooning¹³, IL Andrulis¹⁴, T Caldes¹⁵, H Olsson¹⁶, JL Hopper²

From Familial Aspects of Cancer 2011 Research and Practice: A combined meeting of kConFab, Australian Breast Cancer Family Study, Australian Colorectal Cancer Family Study, Australian Ovarian Cancer Study, Family Cancer Clinics of Australia and New Zealand and kConFab Kingscliff, Australia. 23-26 August 2011

Background

The efficacy of tamoxifen as a breast cancer (BC) prevention strategy for *BRCA1* and *BRCA2* mutation carriers is uncertain.

Patients and methods

Female *BRCA1* and *BRCA2* mutation carriers, with a personal history of BC since 1970, enrolled in any of the BC family studies, kConFab (Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer), IBCCS (International *BRCA1* and *BRCA2* Carrier Cohort Study), or BCFR (Breast Cancer Family Registry) were eligible. Those with bilateral disease at first BC diagnosis, tamoxifen use prior to their first BC diagnosis, or another invasive cancer with were excluded. Data were self-reported at entry into the cohort and at follow-up. Hazard ratios (HRs) for development of contralateral BC associated with tamoxifen use after first BC diagnosis were estimated using Cox proportional hazards, modeling time from diagnosis of first primary BC, adjusting for year of birth (continuous), age at diagnosis (continuous), country and bilateral oophorectomy (yes/no, time-varying). Data were censored at contralateral mastectomy, death or loss to follow-up.

Results

Of 1642 *BRCA1* and 919 *BRCA2* mutation carriers, 374 (23%) and 444 (48%), respectively, took tamoxifen after

their first BC diagnosis. During 21,344 person-years of follow-up, 596 contralateral BCs were observed. Overall, the adjusted HR estimates were 0.31 (95% CI: 0.22-0.45) and 0.24 (95% CI 0.16-0.35) for *BRCA1* and *BRCA2* mutation carriers, respectively. After left-truncating the analysis at time of recruitment, the adjusted HR estimates were 0.52 (95% CI: 0.26-1.04) and 0.39 (95% CI: 0.17-0.89) from studying 629 *BRCA1* and 412 *BRCA2* mutation carriers, respectively, with 4,869 person-years of follow-up.

Conclusions

Although biased estimates due to non-random use of tamoxifen cannot be excluded, these results are consistent with tamoxifen reducing BC risk for both *BRCA1* and *BRCA2* mutation carriers.

Author details

¹Peter MacCallum Cancer Centre, Melbourne, Australia. ²University of Melbourne, Melbourne, Australia. ³Netherlands Cancer Institute, Amsterdam, Netherlands. ⁴University of Utah, Salt Lake City, USA. ⁵Prince of Wales Hospital, Randwick, Australia. ⁶St Vincent's Hospital, Melbourne, Australia. ⁷Huntsman Cancer Institute, Salt Lake City, USA. ⁸University of Cambridge, Cambridge, UK. ⁹Columbia University, New York, USA. ¹⁰Fox Chase Cancer Center, Philadelphia, USA. ¹¹Institut Curie, Paris, France. ¹²Northern California Cancer Center, Fremont, USA. ¹³Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, Netherlands. ¹⁴Ontario Cancer Genetics Network, Cancer Care Ontario, Toronto, Canada. ¹⁵Hospital Clinico San Carlos, Madrid, Spain. ¹⁶Lund University Hospital, Lund, Sweden.

Published: 12 April 2012

¹Peter MacCallum Cancer Centre, Melbourne, Australia
Full list of author information is available at the end of the article

doi:10.1186/1897-4287-10-S2-A11

Cite this article as: Phillips *et al.*: Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *Hereditary Cancer in Clinical Practice* 2012 **10**(Suppl 2): A11.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

